112 results about "T790M" patented technology

The invention relates to an arylaminopyrimidine or triazine derivative, and a preparation method, a medicinal composition and a use thereof, and concretely relates to a compound represented by formula I, or a pharmaceutically acceptable salt or a solvate thereof. In the formula I, R1 to R7, X and Y are defined in the description and claims. The invention also relates to a preparation method of the compound of formula I, the medicinal composition containing the compound, and the pharmacy use of the compound and the medicinal composition. The compound of formula I is an effective tyrosine kinase irreversible inhibitor, and especially has a strong inhibition effect on EGFR-T790M drug-resistant tumors.

The invention relates to pentadeuteropyridine compounds represented by the following formula (I) and pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, and a preparation method, pharmaceutical compositions and uses thereof. The compounds can generate an inhibitory effect on variation forms of epidermal growth factor receptor (EGFR) protein kinase, thereby effectively inhibiting the growth of a variety of tumor cells; the compounds can be used for preparation of antitumor drugs, are used for treatment or prevention of a plenty of different cancers, and moreover, can overcome the drug resistance induced by conventional drugs gefitinib, erlotinib and other first-generation EGFR inhibitors. More specifically, the compounds can be used for preparation of drugs for treatment or prevention of diseases, obstacles, disorders or illness conditions mediated by certain variation-form epidermal growth factor receptors (such as L858R activated mutants, Exon19 deletion activated mutants, and T790M resistance mutants).

The invention relates to a 2-arylaminopyridine, pyrimidine or triazine derivative and a preparation method and application thereof. The 2-arylaminopyridines, pyrimidines or triazine derivatives may act on certain mutant forms of epidermal growth factor receptors such as L858R activating mutants, delE746_A750 mutants, Exonl9 deletion activating mutants and T790M drug resistant mutants , for use in the treatment and prevention of diseases and conditions. The 2-arylaminopyridine, pyrimidine or triazine derivatives are useful for the treatment and prevention of cancer. The present invention also relates to pharmaceutical compositions comprising 2-arylaminopyridines, pyrimidines or triazine derivatives, intermediates useful in the preparation of 2-arylaminopyridines, pyrimidines or triazine derivatives, and the use of 2-arylamino Pyridine, pyrimidine or triazine derivatives in the treatment of diseases mediated by various forms of EGFR.

The invention discloses an EGFR inhibitor. The EGFR inhibitor is of the structure shown in the formula (I) and is a compound including alpha, beta-unsaturated carboxylic acid amides. Meanwhile, the invention discloses a preparing method of the compound and the application of the compound serving as a protein tyrosine kinase inhibitor, especially the inhibiting function on T790M variant EGFR as the EGFR inhibitor, and the application on treating diseases such as the kidney cancer, the ling cancer, the prostate cancer, the pancreatic cancer the breast cancer and the spongiocytoma which are related to EGFR over expression. The structure is shown in the specification.

The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDK1, Chk (e.g. Cbk1 or Chk2), FGFR (e.g. FGFR3), Ret, Eph (e.g. EphB2 or EphB4), or Src (e.g. cSrc); or B. a cancer in which the cancer cells thereof contain a drug resistant kinase mutation which is: (a) a threonine gatekeeper mutation; or (b) a drug-resistant gatekeeper mutation; or (c) an imatinib resistant mutation; or (d) a nilotinib resistant mutation; or (e) a dasatinib resistant mutation; or (f) a T670I mutation in KIT; or (g) a T674I mutation in PDGFR; or (h) T790M mutation in EGFR; or (i) a T315I mutation in abl; or C. a cancer which expresses a mutated molecular target which is a mutated form of BCRabl, c-kit, PDGF, EGF receptor or ErbB2; or D. a disease mediated by a kinase containing a mutation in a region of the protein that binds to or interacts with other cancer agents but does not bind to or interact with the compounds of formula (I) or (I′), for example a mutated kinase selected from c-abl, c-kit, PDGFR including PDGFR-beta and PDGFR-alpha, and ErbB family members such as EGFR (ErbB1), HER2 (ErbB2), ErbB3, and ErbB4, members of the Ephrin receptor family including EphA1, EphA2, EphA3, EphA4, EphA5, EphA8, EphA10, EphB1, EphB2, EphB3, EphB5, EphB6, c-Src and kinases of the JAK family such as TYK2; wherein the compound is a compound of the formula (I or I′): or a salt, solvate, tautomer or N-oxide thereof wherein R^0′, R¹, R^1′, R^2′, R^3′, R^4′, A′, X′, E, A and M are as defined in the claims.

The invention discloses a primer pair for specific amplification of EGFR gene 20 exon T790M and C797S loci. The sequence of the primer pair is shown in SEQ ID No:1-2. The invention further discloses a probe set for specific detection of the T790M and C797S loci. The probe set comprises a wild type probe and a mutant type probe, and the sequences are shown in SEQ ID No:3-7. The invention further discloses a reagent kit comprising the primer pair and the probe set, and a method for adopting the primer pair and the detection set for detecting EGFR gene 20 exon T790M and C797S mutation. By designing the specific primers and probes, the 3' end of the probes is connected with a minor groove binder and a non-fluorescent quenching group, the interference of background signals is lowered, hybridization of the probes and a template is stabilized, a Tm value of the probes is increased, and therefore the mutation detection sensitivity is improved.

Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.

The invention relates to a tricyclic compound of the formula (I) and the formula (II) and pharmaceutical acceptable salts of the tricyclic compound. The compounds of the kind can be applied to inhibit mutants, such as EGFR (L858R), EGFR (delE746-A750) and EGFR (T790M), of EGFR kinase, and can also be used for treating cancer, such as the non-small cell lung cancer, caused by the mutants of the EGFR. The invention further relates to pharmaceutical compositions containing the compounds of the kind, methods for preparing the compounds of the kind and application of the compounds of the kind or the pharmaceutical compositions for preparing medicines for treating the cancers caused by the mutants of the EGFR.

The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

The present invention relates to a tricyclic compound of formula (I) and a pharmaceutically acceptable salt thereof. The compound can be used for inhibiting mutants of epidermal growth factor receptor(EGFR) kinases, such as EGFR (delE746-A750), EGFR (L858R), EGFR (delE746-A750/T790M), EGFR (L858R/T790M), EGFR exon 20insertion and other mutants, so the compound can be used to treat cancer caused by EGFR mutants, such as non-small cell lung cancer. The invention also relates to a medicinal composition containing the compound, a method for preparing the compound, and an application of the compound or the medicinal composition in the preparation of medicines for treating the cancers caused by EGFR mutants.

The invention discloses probes, primers and a kit for detecting a T790M mutation of an EGFR gene. The probes and the primers have the following sequence: SEQ ID NO: 01 to SEQ ID NO. 07. The probes, the primers and the kit have the following benefits: (1) SNP sites on the primers are designed as G/A merged basic groups, so that all efficiencies are compatible, and the amplification efficiency is improved; (2) the sensitivity is high, that is, the detection sensitivity can reach 2 permillage; (3) compared with those adopting a digital PCR method, the operation is simple, the cost is reduced, and the clinical application range is wide; (4) through blood plasma sample detection with a large reaction volume, the DNA loading quantity of blood plasma samples is increased, the detection system is more stable, and the detection rate of the blood plasma samples is improved; (5) the detection speed is high, that is, the detection process can be completed within only 120 minutes, and the time consumed in the detection process is only a half of that consumed according to the digital PCR method; (6) the probes, the primers and the kit, provided by the invention, can be utilized for detecting peripheral blood samples, so that convenient sampling and dynamic detection can be realized.

The invention discloses a selectivity inhibitor of a clinical mutant of EGFR protein tyrosine kinase. The selectivity inhibitor of the clinical mutant of EGFR protein tyrosine kinase has a structure which is shown in the formula (1) (The formula (1) is defined in the description), and is a double aromatic nucleus template compound containing quinazoline, pyridopyrimidine or pyrimidopyrimidine. The invention further discloses a preparing method of the compound and an application of the compound as the selectivity inhibitor of the clinical mutant of EGFR protein tyrosine kinase, especially an inhibiting effect of the compound in a T790M-variation EGFR and an application in treating diseases such as renal carcinoma, lung cancer, prostate gland cancer, pancreatic cancer, breast cancer and spongiocytoma, wherein the diseases are related to overexpression of the epidermal growth factor receptor EGFR.

The invention discloses quinazoline derivatives serving as irreversible tyrosine kinase inhibitors, and use of the derivatives as inhibitors for human epidermal growth factor receptor (EGFR) mutant T790M and anticancer agents. The invention also relates to a preparation method for the quinazoline derivatives, and a medicinal composition containing the quinazoline derivatives.

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.

The invention relates to an enzyme digestion enriched PCR method used in noninvasive detection of epidermal growth factor receptor T790M mutation, and belongs to the field of molecular biology. The invention aims at solving a clinical application bottleneck problem of NSCLC patient EGFR gene T790M mutation detection. According to the nucleotide differences between EGFR gene T790M mutant and wild-type sequences, proper PCR primers are designed, and are introduced into specific restriction endonuclease site during a PCR amplification process, and the EGFR gene T790M mutation enzyme digestion enriched PCR method is established. The method provided by the invention is mainly advantages in that: time required by the detection method is greatly shorter than that of common sequencing technologies; target sequence PCR amplification is carried out by using an enzyme digestion enriching method, and is used in detection, such that the interference caused by a large amount of wild-type sequence in the product to the detection result is avoided; the detection method steps are simple; a second-round PCR product is analyzed through mutant gene fragment specific restriction endonuclease digestion, such that mutant gene sequence can be accurately detected, and detection accuracy can be greatly improved; sampling is convenient, patient pain is low, and dynamic detection can be carried out.

The invention discloses a kit for EGFR gene mutation detection and application, and belongs to the fields of biotechnology and medicine. Compared with the prior art, the kit has the advantages that aprimer, a probe and the kit of an amplification system are high in detection sensitivity, and can detect specimens with the mutation content being smaller than 0.1 percent; the detection accuracy is high, a double control detection system and a locked nucleic acid technology are adopted, and the reliability of detection results is guaranteed; only 8 reactions are needed, including EGFR quality control reaction liquid, L858R detection reaction liquid, 19del detection reaction liquid, G719X detection reaction liquid, L861Q detection reaction liquid, 3Ins20 detection reaction liquid, T790M detection reaction liquid and S768I detection reaction liquid, to be used for detecting 29 common mutant types of EGFR gene in serum or plasma and tissue samples of non-small cell lung cancer patients.

The invention discloses a quantitative standard substance for BRAF and EGFR gene mutation detection, a preparation method and a valuing method thereof. The method comprises the following steps: respectively establishing plasmids containing BRAF gene V600E, EGFR gene T790M, L858R and deletion mutant E746_A750del mutation site, taking the plasmids as a template for performing PCR amplification, acquiring a PCR product and performing Sanger sequencing verification, and then using a scale for weighting ultrasonic fragmented wild type human genomic DNA and mixing at a certain ratio, thereby acquiring the quantitative standard substance with BRAF gene V600E mutant, EGFR gene T790M, L858R and deletion mutant E746_A750del mutant. The invention provides the preparation method for the quantitative standard substance. The fragmented wild type human genomic DNA is used as background DNA, so that the background for practically detecting a free DNA sample can be simulated. The valuing method for the quantitative standard substance is high in precision and accuracy and is independent from DNA standard substance and the measuring result can be traced to international basic unit (weight), so that the reliability and the traceability of the measuring result can be guaranteed.

Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.

Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del) the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.

The invention provides pyrrolopyrimidine compounds containing m-chloroaniline substituents as well as a preparation method and application of the pyrrolopyrimidine compounds, and particularly relatesto compounds represented by a formula (I) shown in the specification, and isomers, hydrates, solvates, pharmaceutically acceptable salts and prodrugs of the compounds, a preparation method of the compounds, and the isomers, hydrates, solvates, pharmaceutically acceptable salts and prodrugs of the compounds and applications of the compounds, and the isomers, hydrates, solvates, pharmaceutically acceptable salts and prodrugs of the compounds in preparation of drugs used as a kinase inhibitor. The compounds provided by the invention have good inhibitory activity on mutant EGFR<T790M> and EGFRC<797S> kinases, and shows moderate inhibitory activity on wild EGFR kinase at the same time.

The invention relates to the field of gene mutation detection, and discloses a PCR kit for detecting EGFR gene T790M mutation. The PCR kit comprises a nucleic acid amplification reagent and a reference substance, wherein the nucleic acid amplification reagent comprises EGFR T790M reaction solution which comprises a specific primer and a fluorescent probe for detecting the EGFR gene T790M mutation;the reaction solution further comprises a pair of upstream primer and downstream primer and an MGB fluorescent probe; the nucleic acid amplification reagent further comprises 2*QuantStudio 3D DigitalPCR Mix. The invention furthermore discloses a detection method of the PCR kit for detecting EGFR gene T790M mutation. The kit uses digital PCR technology to quantitatively detect T790M mutations intissues or plasma DNA samples of non-small cell lung cancer patients, thereby assisting the formulation of targeted drug treatment protocols for patients.

The invention belongs to the technical field of pharmaceutical chemistry, and relates to a quinazoline derivate with a general formula (I) as well as the preparation method and the application thereof, wherein both R1 and R2 have meanings defined in an instruction. The invention also relates to the preparation method of the derivative. The derivative and inorganic and organic acid or alkali form salt which is acceptable physiologically, and drug combinations containing the derivative. The compound has valuable pharmacological properties and especially plays a role in restraining signal transduction aroused by tyrosine kinase; and particularly, a mutant EGFR (Epidermal Growth Factor Receptor) (L858R/T790M) and HER 2 have higher inhibitory activity. The invention also relates to a method for treating diseases, in particular to diseases characterized in abnormal erbB PTK (protein tyrosine kinase) activity. The general formula (I) is as follows.